Special 12/2012

  • BIO-Regions in the European Union

    In an era of tight purse-strings when it comes to collecting capital for long-term projects like drug development, the concentration of know-how in a biotech cluster, incubator or meta-cluster offers bio­tech companies many advantages. Access to a common infrastructure and networks, better visibility for potential corporate and VC investors, and improved access to public funding are only a few of them. Well­­-established biotech hubs also exert an irresistible appeal to national and EU policymakers. They of course are seeking to create high-paying jobs, attract new companies as well as investors and stimulate the socioeconomic growth of entire regions (see p. 38). In this special, EuroBio­techNews presents some of the strategies that European bio-incubators are implementing in their quests to become the next major global hub.

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/spezial/2012/12/pos/1.html?cHash=8305edff5982cb307c5ea48106acb36a&sort=desc

Kurszettel

Alle Kurse

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THROMBOGENICS (B)9.54 EUR-5.07%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.77 EUR-29.2%
  • PROSENSA (NL)9.81 USD-22.6%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.5%

No liability assumed, Date: 25.07.2014